SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001193125-19-186075
Filing Date
2019-06-28
Accepted
2019-06-28 16:30:57
Documents
3
Group Members
EDWIN M. KANIA, JR.FLAGSHIP PIONEERING FUND VI GENERAL PARTNER LLCFLAGSHIP PIONEERING FUND VI, L.P.FLAGSHIP PIONEERING, INC.FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLCFLAGSHIP VENTURES FUND IV, L.P.FLAGSHIP VENTURES FUND IV-RX, L.P.NOUBAR B. AFEYAN, PH.

Document Format Files

Seq Description Document Type Size
1 SC 13D d48072dsc13d.htm SC 13D 200503
2 EX-99.1 d48072dex991.htm EX-99.1 14328
3 EX-99.2 d48072dex992.htm EX-99.2 29186
  Complete submission text file 0001193125-19-186075.txt   246069
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Subject) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-88909 | Film No.: 19929824
SIC: 2834 Pharmaceutical Preparations

Mailing Address 55 CAMBRIDGE PARKWAY, 8TH FLOOR CAMBRIDGE MA 02143
Business Address 55 CAMBRIDGE PARKWAY, 8TH FLOOR CAMBRIDGE MA 02143 617-868-1888
Flagship VentureLabs IV, LLC (Filed by) CIK: 0001642578 (see all company filings)

IRS No.: 461974736 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D